Nick Leschly, bluebird bio CEO (Jeff Rumans)
February 23, 2021 05:34 PM ESTUpdated February 24, 07:13 AM
FDA+

It's of­fi­cial: FDA clamps a hold on blue­bird's trou­bled Lenti­Glo­bin pro­gram while EMA con­sid­ers new mea­sures

John Carroll

Editor & Founder

What start­ed out as a vol­un­tary hold of a crit­i­cal de­vel­op­ment pro­gram at blue­bird bio has gone in­to an of­fi­cial lock­up at the FDA. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times